Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Chief Medical Officer | April 23, 2026 | April 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date April 23, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 226,958 |
Reported balance
After 2026-04-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-23 · Sale · Disposed 10,000 · Balance 226,958 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2022 Filed Jan 7, 2022 01:56 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 9,955 | $64.89 | $645,979.95 |
DisclosureSEC source: 0001209191-22-002284 · doc4.xml · nonDerivative · entry 1 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,295 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 to $65.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:28 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001313 · doc4.xml · nonDerivative · entry 1 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,250 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 22:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,814 | $81.82 | $312,061.48 |
DisclosureSEC source: 0001209191-21-003871 · doc4.xml · nonDerivative · entry 2 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,250 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.44 to $82.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 22:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,186 | $80.97 | $500,880.42 |
DisclosureSEC source: 0001209191-21-003871 · doc4.xml · nonDerivative · entry 1 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,064 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.40 to $81.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 14,708 | $72.67 | $1,068,830.36 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 7 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,250 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F8 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.43 to $72.89, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,967 | $72.05 | $285,822.35 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 6 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,958 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F7 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.42 to $72.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 06, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 700 | $70.89 | $49,623.00 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 5 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,925 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F6 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.26 to $71.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,925 | $73.93 | $142,315.25 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 4 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,625 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 10,350 | $72.91 | $754,618.50 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 3 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,550 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.60 to $73.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,300 | $72.19 | $238,227.00 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 2 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,900 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.57 to $72.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 23:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,800 | $71.09 | $270,142.00 |
DisclosureSEC source: 0001209191-21-002571 · doc4.xml · nonDerivative · entry 1 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,200 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.52 to $71.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:07 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001510 · doc4.xml · nonDerivative · entry 1 Hamilton James C · CIK 0001830755 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.